Madelyn Burkart

1.4k total citations
24 papers, 425 citations indexed

About

Madelyn Burkart is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Madelyn Burkart has authored 24 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 8 papers in Genetics and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Madelyn Burkart's work include Acute Myeloid Leukemia Research (13 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Madelyn Burkart is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Madelyn Burkart collaborates with scholars based in United States, Australia and Georgia. Madelyn Burkart's co-authors include Patrick H. Nachman, Elisabeth A. Berg, Yichun Hu, Ronald J. Falk, Caroline J. Poulton, Susan L. Hogan, Reem Karmali, John L. Niles, Coen A. Stegeman and A. Richard Kitching and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Madelyn Burkart

19 papers receiving 422 citations

Peers

Madelyn Burkart

PRM

IMMUN

RHEUM

GENET

Peter A. Merkel United States

Corrado Murtas Italy

Loren Herrera Hernandez United States

Jane Hollis United Kingdom

Turki Al‐Hussain Saudi Arabia

Pankti Reid United States

Corentin Orvain France

Angela Amendola Italy

Sheila Santín Spain

Nadjat Mounedji France

Peter A. Merkel United States

Madelyn Burkart

376 ×1.6

PRM

218 ×1.7

IMMUN

169 ×1.9

RHEUM

61 ×0.8

169 ×2.1

GENET

Citations per year, relative to Madelyn Burkart Madelyn Burkart (= 1×) peers Peter A. Merkel

Countries citing papers authored by Madelyn Burkart

Since Specialization

Citations

This map shows the geographic impact of Madelyn Burkart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madelyn Burkart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madelyn Burkart more than expected).

Fields of papers citing papers by Madelyn Burkart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Madelyn Burkart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madelyn Burkart. The network helps show where Madelyn Burkart may publish in the future.

Co-authorship network of co-authors of Madelyn Burkart

This figure shows the co-authorship network connecting the top 25 collaborators of Madelyn Burkart. A scholar is included among the top collaborators of Madelyn Burkart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madelyn Burkart. Madelyn Burkart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hantel, Andrew, Yating Wang, Ivy Abraham, et al.. (2024). Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.. Journal of Clinical Oncology. 42(16_suppl). 1589–1589.

Jain, Akriti, Madelyn Burkart, Xiaoyue Ma, et al.. (2024). Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2867–2867.

Burkart, Madelyn & Shira Dinner. (2024). Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia. Blood Reviews. 66. 101208–101208. 1 indexed citations

Abraham, Ivy, Madelyn Burkart, Hamed Rahmani Youshanlouei, et al.. (2024). Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Advances. 8(17). 4647–4650. 2 indexed citations

Pardee, Timothy S., Rupali Bhave, Leslie R. Ellis, et al.. (2024). The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2858–2858.

Badar, Talha, Ehab Atallah, Rory M. Shallis, et al.. (2023). Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 37(4). 799–806. 29 indexed citations

Badar, Talha, Mark R. Litzow, Rory M. Shallis, et al.. (2022). Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer. 129(6). 934–945. 5 indexed citations

Badar, Talha, Ehab Atallah, Antoine N. Saliba, et al.. (2022). Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood. 140(Supplement 1). 6058–6060. 1 indexed citations

Badar, Talha, Mark R. Litzow, Rory M. Shallis, et al.. (2022). Racial disparities in patients with TP53 mutated acute myeloid leukemia.. Journal of Clinical Oncology. 40(16_suppl). e19007–e19007. 1 indexed citations

10.

Badar, Talha, Ehab Atallah, Rory M. Shallis, et al.. (2022). Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood. 140(Supplement 1). 1435–1437. 2 indexed citations

11.

Burkart, Madelyn, et al.. (2022). Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse. SHILAP Revista de lepidopterología. 2022. 1–4.

12.

Patel, Anand, Evan C. Chen, Madelyn Burkart, et al.. (2022). Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies. Blood. 140(Supplement 1). 6860–6862. 6 indexed citations

13.

Jain, Akriti, Madelyn Burkart, Christopher Famulare, et al.. (2021). Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 32–32. 13 indexed citations

14.

Burkart, Madelyn, Olga Frankfurt, Carlos E. Vigil, et al.. (2021). Outcomes and Predictors of Relapse with Use of Hypomethylating Agents in Combination with Venetoclax Prior to Allogeneic Transplant in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 2327–2327. 1 indexed citations

15.

Gao, Juehua, Madelyn Burkart, Masha Kocherginsky, et al.. (2020). Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. Leukemia. 35(7). 2097–2101. 8 indexed citations

16.

Burkart, Madelyn, Michael Schieber, Sanjib Basu, et al.. (2019). Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. British Journal of Haematology. 186(1). 45–53. 31 indexed citations

17.

Burkart, Madelyn, Stacy D. Sanford, Shira Dinner, Lisa K. Sharp, & Karen E. Kinahan. (2018). Future health of AYA survivors. Pediatric Blood & Cancer. 66(2). e27516–e27516. 22 indexed citations

18.

Berg, Elisabeth, Madelyn Burkart, Caroline J. Poulton, et al.. (2014). What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population. PubMed. 2(3). 74–91. 4 indexed citations

19.

Roth, Aleeza J., Joshua D. Ooi, Mirjan M. van Timmeren, et al.. (2013). Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. Journal of Clinical Investigation. 123(4). 1773–1783. 184 indexed citations

20.

Bunch, Donna O., Madelyn Burkart, Yichun Hu, et al.. (2013). Decreased CD5+ B Cells in Active ANCA Vasculitis and Relapse after Rituximab. Clinical Journal of the American Society of Nephrology. 8(3). 382–391. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact